Cargando…

Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas

SIMPLE SUMMARY: Pediatric ependymomas are malignant pediatric brain tumors, and one-third of patients exhibit recurrence within two years of initial treatment. Therefore, this study aimed to find new agents to overcome these chemoresistant tumors and defer radiotherapy treatment. By using integrated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Muh-Lii, Chen, Chun-Han, Liu, Yun-Ru, Huang, Man-Hsu, Lin, Yu-Chen, Wong, Tai-Tong, Lin, Sey-En, Chu, Shing-Shiung, Ding, Yi-Huei, Hsieh, Tsung-Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760843/ https://www.ncbi.nlm.nih.gov/pubmed/33271970 http://dx.doi.org/10.3390/cancers12123597

Ejemplares similares

MODL-16. ABEMACICLIB, A SELECTIVE CDK4/6 INHIBITOR, RESTRICTS GROWTH OF PEDIATRIC GLIAL-LINEAGE TUMORS IN VITRO AND IN VIVO
por: Liang, Muh-Lii, et al.
Publicado: (2020)

Combining an Autophagy Inhibitor, MPT0L145, with Abemaciclib Is a New Therapeutic Strategy in GBM Treatment
por: Hsieh, Tsung-Han, et al.
Publicado: (2021)

Significance of cyclin D1 overexpression in progression and radio-resistance of pediatric ependymomas
por: Liang, Muh-Lii, et al.
Publicado: (2017)

Application of Drug Testing Platforms in Circulating Tumor Cells and Validation of a Patient-Derived Xenograft Mouse Model in Patient with Primary Intracranial Ependymomas with Extraneural Metastases
por: Liang, Muh-Lii, et al.
Publicado: (2023)

Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas
por: Liang, Muh-Lii, et al.
Publicado: (2016)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
por: Wander, Seth A, et al.
Publicado: (2022)

Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy
por: Gharbi, Severine Isabelle, et al.
Publicado: (2022)

Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
por: Sun, Chao-Yue, et al.
Publicado: (2022)

Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression
por: Lin, Yueh-Te, et al.
Publicado: (2021)

An UHPLC-MS/MS method for quantification of the CDK4/6 inhibitor abemaciclib in human serum
por: Habler, Katharina, et al.
Publicado: (2022)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)

Author Correction: Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy
por: Gharbi, Severine Isabelle, et al.
Publicado: (2022)

Abemaciclib for breast cancer
Publicado: (2020)

Mechanisms of abemaciclib, a CDK4/6 inhibitor, induced apoptotic cell death in prostate cancer cells in vitro
por: Guney Eskiler, Gamze, et al.
Publicado: (2021)

Extramedullary tanycytic ependymoma of the lumbar spinal cord
por: Kim, Dong Ja, et al.
Publicado: (2019)

Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth
por: Bouclier, Celine, et al.
Publicado: (2020)

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
por: La Monica, Silvia, et al.
Publicado: (2020)

Integrated genomics has identified a new AT/RT-like yet INI1-positive brain tumor subtype among primary pediatric embryonal tumors
por: Ho, Donald Ming-Tak, et al.
Publicado: (2015)

Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center‐derived B‐cell lymphomas
por: Tanaka, Yuka, et al.
Publicado: (2020)

The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018)

Abemaciclib: A multi-functional radiation modifier
por: Naz, Sarwat, et al.
Publicado: (2019)

Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study
por: de Luna Aguilar, Alicia Milagros, et al.
Publicado: (2023)

TESC Promotes TGF-α/EGFR-FOXM1-Mediated Tumor Progression in Cholangiocarcinoma
por: Hsieh, Cheng-Han, et al.
Publicado: (2020)

Ependymomas
por: Bertero, Luca, et al.
Publicado: (2022)

Pediatric primary central nervous system germ cell tumors of different prognosis groups show characteristic miRNome traits and chromosome copy number variations
por: Wang, Hsei-Wei, et al.
Publicado: (2010)

Determining the critical effective temperature and heat dispersal pattern in monopolar radiofrequency ablation using temperature-time integration
por: TSENG, HOW, et al.
Publicado: (2016)

Profile of abemaciclib and its potential in the treatment of breast cancer
por: Martin, James M, et al.
Publicado: (2018)

Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib
por: Omarini, Claudia, et al.
Publicado: (2020)

Abemaciclib/fulvestrant: Leucopenia and Covid-19: case report
Publicado: (2020)

Drug-Induced Eosinophilic Pneumonia as an Adverse Event of Abemaciclib
por: Mitarai, Yuki, et al.
Publicado: (2022)

Clinicoradiological course of abemaciclib-induced pneumonitis with histology findings
por: Okayasu, Kaori, et al.
Publicado: (2023)

An experimental study: the effect of S. boulardii on abemaciclib-induced diarrhea
por: CAKCAK, İbrahim Ethem, et al.
Publicado: (2022)

Sacrococcygeal myxopapillary ependymoma with anaplastic ependymoma component in an infant
por: Chakraborti, Shrijeet, et al.
Publicado: (2012)

CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease
por: Kosovec, Juliann E., et al.
Publicado: (2017)

Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications
por: Oner, Muhammet, et al.
Publicado: (2019)

Multi-Disciplinary Treatment of a Rare Pelvic Cavity Ependymoma
por: Hwang, Hye Jin, et al.
Publicado: (2007)

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
por: Torres-Guzmán, Raquel, et al.
Publicado: (2017)

Molecular docking and machine learning analysis of Abemaciclib in colon cancer
por: Liñares-Blanco, Jose, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_akdcd2ddvod92pmg99od3ciguc